Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track

Gossamer Bio, Inc.

2024-Q2 EPS reported $0.03 revenue$95,842,000

Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.
Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.
Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.
R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).
PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.